April, 2012
CEO Morten Nielsen interview in World Pharmaceutical Frontiers, April 2012 edition

To meet the increasing demands for more benefit-driven devices and solutions, pharmaceutical companies must make a step-change in how devices are tailored. Morten Nielsen, CEO of Bang & Olufsen Medicom, reveals how his firm has facilitated this challenge, while investing in market-driven technology accelerators to enable the innovation of differentiated device solutions.

Direct link to article: World Pharmaceutical Frontiers, April 2012 edition

For pdf-version of published article, press here

February, 2012
Bang & Olufsen Medicom signs deal with leading Pharmaceutical company

The innovative drug delivery device company Bang & Olufsen Medicom have signed a significant multimillion Euro Licensing & Development Agreement with a leading pharmaceutical company for an advanced and highly differentiated electronic auto-injector. Furthermore Bang & Olufsen Medicom will have exclusive global manufacturing rights and be legal manufacturer of the new device in all major markets and will also retain certain rights to the licensed technology. This is a significant commercial milestone for Bang & Olufsen Medicom, and will take advantage of the integrated Services of the company - ranging from innovative user-centric design, integration of mechanics, electronics and software over regulatory approvals to low-volume manufacturing.

March, 2012
Bang & Olufsen Medicom signs new major deal with International Pharmaceutical company

The innovative drug delivery device company Bang & Olufsen Medicom have signed a significant Development Agreement with an international pharmaceutical company for highly innovative and differentiated auto-injector for a very competitive market driven by high standards for patient convenience and safety. Bang & Olufsen Medicom will, apart from being responsible for the development of the device, undertake the overall project management on the behalf the client and secure tech transfer to a leading contract manufacturing organization.
The device is based on Bang & Olufsen Medicom innovative injection technology accelerators and Bang & Olufsen Medicom will have exclusive global rights to the developed product and technologies outside the client field of operation.
This is yet another significant commercial milestone for Bang & Olufsen Medicom, and will take advantage of the integrated Services of the company - ranging from innovative user-centric design, development of complex mechanical solution to tech transfer process, including project management of multi-company projects.